Cellectar Biosciences (CLRB) Current Assets (2010 - 2026)
Cellectar Biosciences (CLRB) posted Current Assets of $14.0 million for Q4 2025, up 3.06% sequentially from $13.6 million in Q3 2025, and down 42.11% YoY from $24.3 million in Q4 2024.
Cellectar Biosciences (CLRB) Current Assets (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Current Assets for 16 years, with the latest figure at $14.0 million in Q4 2025.
- Quarterly Current Assets fell 42.11% year-over-year to $14.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.0 million (down 42.11% YoY) and the FY2025 annual result came in at $14.0 million, down 42.11% from the prior year.
- Current Assets climbed to $14.0 million in Q4 2025 per CLRB's latest filing, from $13.6 million in the prior quarter.
- Over five years, Current Assets peaked at $54.4 million in Q1 2021 and troughed at $5.6 million in Q2 2023.
- A 5-year average of $25.5 million and a median of $22.4 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2021 and 2023: Current Assets soared 591.83% in 2021, then tumbled 77.81% in 2023.
- Over 5 years, Current Assets stood at $36.6 million in 2021, then sank by 43.86% to $20.5 million in 2022, then sank by 49.08% to $10.5 million in 2023, then jumped by 131.99% to $24.3 million in 2024, then plunged by 42.11% to $14.0 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $14.0 million, $13.6 million, and $12.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | 34.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.88 Mn |
| Dec 31, 2025 | 14.04 Mn |
| Sep 30, 2025 | 13.62 Mn |
| Jun 30, 2025 | 12.62 Mn |
| Mar 31, 2025 | 14.89 Mn |
| Dec 31, 2024 | 24.25 Mn |
| Sep 30, 2024 | 35.90 Mn |
| Jun 30, 2024 | 27.91 Mn |
| Mar 31, 2024 | 41.37 Mn |
| Dec 31, 2023 | 10.45 Mn |
| Sep 30, 2023 | 20.11 Mn |
| Jun 30, 2023 | 5.61 Mn |
| Mar 31, 2023 | 13.85 Mn |
| Dec 31, 2022 | 20.53 Mn |
| Sep 30, 2022 | 18.76 Mn |
| Jun 30, 2022 | 25.29 Mn |
| Mar 31, 2022 | 31.39 Mn |
| Dec 31, 2021 | 36.57 Mn |
| Sep 30, 2021 | 41.39 Mn |
| Jun 30, 2021 | 47.12 Mn |